Technical Analysis for XTLB - XTL Biopharmaceuticals Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Down |
| Historical XTLB trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Fell Below 20 DMA | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -4.58% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/04/2019
- Sector: Healthcare
- Industry: Biotechnology
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. It is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C. The company's lead drug candidate is recombinant human erythropoietin (rHuEPO) for the treatment of multiple myeloma blood cancer, as well as for the treatment of severe anemia. The rHuEPO has also granted an orphan drug designation from the FDA for the treatment of multiple myeloma blood cancer. The company is also developing SAM-101, a proprietary combination of antipsychotic drugs and a medicinal compound, which has completed Phase IIa clinical trials as a therapy for psychotic diseases, with focus on schizophrenia. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Herzliya, Israel.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Natural Sciences Medication Pharmacy Pharmaceutical Products Schizophrenia Multiple Myeloma FDA Hepatitis C
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Natural Sciences Medication Pharmacy Pharmaceutical Products Schizophrenia Multiple Myeloma FDA Hepatitis C
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.75 |
| 52 Week Low | 0.625 |
| Average Volume | 3,028 |
| 200-Day Moving Average | 1.51 |
| 50-Day Moving Average | 1.16 |
| 20-Day Moving Average | 1.31 |
| 10-Day Moving Average | 1.27 |
| Average True Range | 0.12 |
| ADX | 14.92 |
| +DI | 31.53 |
| -DI | 25.37 |
| Chandelier Exit (Long, 3 ATRs ) | 1.09 |
| Chandelier Exit (Short, 3 ATRs ) | 1.44 |
| Upper Bollinger Band | 1.49 |
| Lower Bollinger Band | 1.12 |
| Percent B (%b) | 0.34 |
| BandWidth | 28.23 |
| MACD Line | 0.02 |
| MACD Signal Line | 0.04 |
| MACD Histogram | -0.0149 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.25 | ||||
| Resistance 3 (R3) | 1.25 | 1.25 | 1.25 | ||
| Resistance 2 (R2) | 1.25 | 1.25 | 1.25 | 1.25 | |
| Resistance 1 (R1) | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 |
| Pivot Point | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 |
| Support 1 (S1) | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 |
| Support 2 (S2) | 1.25 | 1.25 | 1.25 | 1.25 | |
| Support 3 (S3) | 1.25 | 1.25 | 1.25 | ||
| Support 4 (S4) | 1.25 |
